Careers
|
Partnerships
|
Contact
|
Login
Response Biomedical logo
RAMP COVID-19 Antigen Test Gets Health Canada Approval

RAMP COVID-19 antigen test gets Health Canada approval

Response Biomedical’s RAMP COVID-19 antigen test gets Health Canada approval.

Response Biomedical Corp. (Response), a global provider of acute care diagnostic testing solutions, is announcing today that Health Canada has granted the RAMP® COVID-19 Antigen Test authorization to commercialize under the Emergency Use Interim Order. The Health Canada authorization allows Response to market and sell the RAMP® COVID-19 Antigen Test to countries that recognize Health Canada authorization.

The RAMP® COVID-19 Antigen Test uses the RAMP® 200 instrument for the detection of SARS-CoV-2 nucleoproteins in nasal swabs from individuals who are suspected of having COVID-19 infection within the first 5 days of symptom onset. The results are delivered in 15 minutes, enabling timely decision-making for healthcare professionals and on-site identification of COVID-19. The test kit contains all required components, including the nasal swabs, to allow for the rapid triage of individuals suspected of SARS-CoV-2 infection.

The RAMP® instrument is a small, automated system capable of storing and transmitting results digitally. The RAMP 200 offers complete traceability and reportability with the flexibility of running one to six tests at a time. 

“As a global provider of acute care tests, it was imperative for us to join the fight against the pandemic for Canada. The addition of the COVID-19 Antigen Test on our RAMP platform completes our panel of tests that have been used globally in the fight against COVID-19 since the start of the pandemic.” stated Dr. Barb Kinnaird, CEO of Response.

“At the onset of the pandemic, NGen mobilized funding to support made-in-Canada solutions to combat COVID-19,” said Jay Myers, CEO, NGen. “We are pleased to see that Response Biomedical’s RAMP COVID-19 antigen test has been recognized by Health Canada as a critical tool in our arsenal to protect the health and well-being of Canadians.”

Health Canada’s decision is under Health Canada’s expedited authorization pathway, Interim Order No. 3. As a part of the authorization process, clinical data gathered from prospective clinical studies were included in support of the RAMP COVID-19 Antigen test performance against recognized PCR lab-based tests. The test was developed with advisory support and research and development funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP).

About Response Biomedical Corporation

Response Biomedical Corp. (Response) is a Canadian manufacturer and global supplier of diagnostic tools that aid in the diagnosis of life-threatening diseases. Response focuses on providing lab quality results in minutes and our RAMP® technology delivers a total solution for making better, faster decisions. RAMP® tests are commercially available to aid in the diagnosis of heart attack, congestive heart failure, sepsis, pregnancy and more. The company is passionate about the patient’s experience and our core purpose to save lives globally. For more information about Response, visit www.responsebio.com.

View Other Posts

Contact Our Specialists

24 hour Technical Support available to all RAMP Customers

Faster

Improves turnaround time
for faster triage

Accurate

Provides high quality results
with built in QC

Reliable

Enables clinicians to make
informed decisions
©2025 Response Biomedical. All Rights reserved

You will be able to participate in this research study if you are:

  • 18 years of age or older.
  • In good health.
  • Willing to voluntarily agree to sign the consent form.

You will not be able to participate in this research study if:

  • You are considered/consider yourself to be a vulnerable subject (e.g., nursing home residents, institutionalized persons, pregnant and nursing women, children under the age of 19, prisoners, or persons with decisional incapacity).
  • You are currently diagnosed with, or have a history of, underlying major medical conditions (for example: heart disease, hypertension, stroke, renal disease, diabetes and bleeding disorders).
  • You are actively in hemodialysis treatment.
  • You have been told that you have HIV, chronic active hepatitis B, or chronic, active hepatitis C.
  • You have been hospitalized (for more than 24 hours) in the past three months.
  • You are actively receiving treatment or monitoring for certain cancers (excluding non-melanoma skin cancers and localized prostate cancer not requiring systemic therapy).
  • You are already enrolled in this study.
  • You are unable and/or unwilling to provide informed consent.
If you are interested in participating in this study, you can schedule a time to virtually meet with the clinical team at Response Biomedical. During your online meeting, Response Biomedical will send you a self-assessment questionnaire via DocuSign to determine eligibility. If you are eligbile to participate, a team member will explain the study in detail, review the consent form with you, and send the consent form to you for electronic signature. Once you have signed the consent form, the study staff will arrange an appointment for you at a nearby LifeLabs location.

To participate in this study at a LifeLabs location, you will need to be able to print a paper copy of the requisition to take with you to your appointment. If you do not have access to a printer but would still like to participate, you can book an appointment at the Response Biomedical location or attend a community collection event.
At your LifeLabs appointment, a trained LifeLabs professional will collect two (2) 4 mL tubes of whole blood—approximately two teaspoons.
After collection, your blood sample will be sent to Response Biomedical, where a trained operator will use it to perform the RAMP® hs-TnI test.

You will be able to participate in this research study if you are:

  • 18 years of age or older.
  • In good health.
  • Willing to voluntarily agree to sign the consent form.

You will not be able to participate in this research study if:

  • You are considered/consider yourself to be a vulnerable subject (e.g., nursing home residents, institutionalized persons, pregnant and nursing women, children under the age of 19, prisoners, or persons with decisional incapacity).
  • You are currently diagnosed with, or have a history of, underlying major medical conditions (for example: heart disease, hypertension, stroke, renal disease, diabetes and bleeding disorders).
  • You are actively in hemodialysis treatment.
  • You have been told that you have HIV, chronic active hepatitis B, or chronic, active hepatitis C.
  • You have been hospitalized (for more than 24 hours) in the past three months.
  • You are actively receiving treatment or monitoring for certain cancers (excluding non-melanoma skin cancers and localized prostate cancer not requiring systemic therapy).
  • You are already enrolled in this study.
  • You are unable and/or unwilling to provide informed consent.
If you agree to take part in this study, study staff will discuss a consent form with you. After you sign the consent form, a phlebotomist will collect a blood sample from you. This will include two (2) 4mL tubes worth of whole blood, which is slightly less than 2 teaspoons. Once the blood has been collected, a trained operator will use your blood sample to perform the RAMP® hs-TnI test. The entire visit should last around 30 minutes.